1191 – 1200 of 1280
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2007
-
Mark
Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
(
- Contribution to journal › Article
-
Mark
Associations between AQT processing speed and neuropsychological tests in neuropsychiatric patients
(
- Contribution to journal › Article
-
Mark
A quick test for cognitive speed: a measure of cognitive speed in dementia with lewy bodies.
(
- Contribution to journal › Article
-
Mark
Soluble adhesion molecules and angiotensin-converting enzyme in dementia.
(
- Contribution to journal › Article
-
Mark
Patients with Lewy body dementia use more resources than those with Alzheimer's disease.
(
- Contribution to journal › Scientific review
-
Mark
Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment
(
- Contribution to journal › Article
-
Mark
Prediction of Alzheimer's Disease Using the CSF Abeta42/Abeta40 Ratio in Patients with Mild Cognitive Impairment.
(
- Contribution to journal › Article
-
Mark
Activities of daily living - Outcome during two years in galantamine treated Alzheimer patients
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Alzheimer's disease - Safety and dropout in long-term galantamine treatment in a routine clinical setting
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Three-year outcome of Galantamine treatment in Alzheimer’s disease in a routine clinical setting.
2007) IPA (International Psychogeriatric Association) 2007 Osaka Silver Congress(
- Contribution to conference › Poster